A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib.

Abstract

Histologic changes can be involved in resistance to anticancer drugs. Transformation to small cell lung carcinoma (SCLC) following treatment with EGFR tyrosine kinase inhibitors has been reported in patients with EGFR-mutant lung adenocarcinoma. Herein, we report a case of ALK-rearranged lung adenocarcinoma with SCLC-like histology in a metastatic abdominal nodule that was resistant to crizotinib therapy.

• Authors: Yoon Jin Cha, Byoung Chul Cho, Hye Ryun Kim, Hye-Jeong Lee, Hyo Sup Shim
• Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (J Thorac Oncol) Vol. 11 Issue 5 Pg. e55-e58 (05 2016) ISSN: 1556-1380 [Electronic] United States
• PMID: 26752677 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Chemical References

• Protein Kinase Inhibitors
• Pyrazoles
• Pyridines
• Crizotinib
• ALK protein, human
• Anaplastic Lymphoma Kinase
• Receptor Protein-Tyrosine Kinases

Topics

• Abdominal Neoplasms (drug therapy, genetics, secondary)
• Adenocarcinoma (drug therapy, genetics, pathology)
• Aged
• Anaplastic Lymphoma Kinase
• Cell Transformation, Neoplastic (drug effects, genetics, pathology)
• Crizotinib
• Drug Resistance, Neoplasm (genetics)
• Gene Rearrangement
• Humans
• Lung Neoplasms (drug therapy, genetics, pathology)
• Male
• Protein Kinase Inhibitors (pharmacology)
• Pyrazoles (pharmacology)
• Pyridines (pharmacology)
• Receptor Protein-Tyrosine Kinases (genetics)
• Small Cell Lung Carcinoma (drug therapy, genetics, pathology)